Successful 5-year Eurobond issue for Mölnlycke

Gothenburg, 31 August 2023: Mölnlycke, a world-leading medtech company, has successfully raised EUR 400M in the corporate bond market under its Euro Medium Term Note (EMTN) programme. The bond has a 5-year tenor with an annual fixed coupon of 4.25% corresponding to mid swaps of +1.18 percentage points.

The bond was more than 3.5 times oversubscribed with an orderbook of over EUR 1,400M at its peak. There was strong and widespread demand from leading investors in Germany, Austria and Switzerland 40%, Nordics 27%, UK & Ireland 23%, France  6%, Other 4%. Asset Managers represented 90% of investors, followed by Banks 5%, and Insurance, Pension Funds and Official Institutions contributed with 5%.

The proceeds will be used for a buy-back of Mölnlycke notes maturing in 2024 as well as for general corporate purposes.

The bond will be listed on the Euro MTF market of the Luxembourg Stock Exchange.

BNP Paribas, Danske Bank, HSBC and SEB acted joint bookrunners for the transaction.

For more information, please contact:

Magnus Nordberg
Corporate Communications & IR Manager 
Email: magnus.nordberg@molnlycke.com
Phone: +46 739 412998

About Mölnlycke^®  

Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. The core business is within the four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and Antiseptics. 

Mölnlycke employs around 8,700 people. The headquarters are in Gothenburg, Sweden, and the company operates in more than 100 countries worldwide. Mölnlycke is owned by Patricia Industries AB, which is part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916. www.molnlycke.com